Hims & Hers Health upgraded to Buy on strong operational focus and growth plans despite sector challenges

Hims & Hers Health has been upgraded from Hold to Buy due to its disciplined operations and strategic growth in personalized treatments and telehealth. The company leverages FDA panel momentum on peptides and emphasizes clinical rigor and supply chain transparency over speed. Despite $974 million in convertible notes and skepticism in the sector, Hims & Hers aims for $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, currently trading at about 2.5 times forward sales. This upgrade reflects confidence in the company’s long-term growth and market approach.